Document:

EX-10.1

 Exhibit 10.1 

AMENDMENT #1 TO 

EMPLOYMENT AGREEMENT 

This AMENDMENT #1 TO EMPLOYMENT AGREEMENT (this “Amendment”) is dated as of February 27, 2014, between Orthofix Inc., a
Minnesota corporation (the “Company”), and Emily Buxton (the “Executive”). 
 WHEREAS, the Executive and
the Company have previously entered into an Employment Agreement on January 7, 2013 (the “Agreement”); and 

WHEREAS, the parties desire to enter into this Amendment to amend and revise the Agreement as set forth herein; 

NOW, THEREFORE, in consideration of the foregoing, the mutual covenants and agreements of the parties contained herein and other good and
valuable consideration, the receipt of which is hereby acknowledged, the parties hereto agree as follows: 
 1. Amendments. 

 

	 	a.	Section 1.1. The second and third sentences of Section 1.1 are hereby amended and restated in their entirety as follows: 

“While serving as an employee of the Company, the Executive shall initially serve as the Company’s Chief Financial Officer, and as
the Parent’s Chief Financial Officer. Subject to Executive’s rights under Section 4.4, the Company and/or Parent may, in its sole discretion, change Executive’s title, position and responsibilities after the date
hereof.” 
  

	 	b.	Section 1.3. Section 1.3 is hereby amended to replace all references to “July 1, 2014” with “July 1, 2015”. 

 

	 	c.	Section 2.2. Section 2.2 is hereby amended to replace the reference to “no less than $296,000” with “$325,000”. 

 

	 	d.	Section 2.3. Section 2.3 is hereby amended to (i) replace the reference to “at least 40%” with “60%” and (ii) replace the reference to “not less than 60%” with
“90%”. 

  

	 	e.	Section 2.6. Article II is amended to add the following text as Section 2.6 thereof. 

2.6 Retention Bonus. The Executive shall be paid a special cash retention bonus of $97,500 (the “First Retention
Bonus”) on the date that the Company has filed each of its financial statement restatement for the 2011 and 2012 fiscal years and the first fiscal quarter of 2013, its Quarterly Reports on Form 10-Q for the second and third fiscal quarters
of 2013, and its Annual Report on Form 10-K for the 2013 fiscal year (the first date by which all such filings have been made, the “First Retention Date”) if (a) Executive remains employed by the Company on the First
Retention Date or (b) Executive’s employment with the Company terminates prior to the First Retention Date pursuant to Sections 4.2, 4.3, 4.4 or 4.5 of this Agreement. The Executive shall be paid an additional special cash retention bonus
of $97,500 (the “Second Retention Bonus”) on the 

 
date that is six months following the First Retention Date (the “Second Retention Date”) if (x) Executive remains employed by the Company on the Second Retention Date
or (y) Executive’s employment with the Company terminates prior to the Second Retention Date pursuant to Sections 4.2, 4.3, 4.4 or 4.5 of this Agreement. If for any reason neither of the applicable conditions set forth in clauses
(a) and (b) (with respect to the First Retention Bonus) or clauses (x) and (y) (with respect to the Second Retention Bonus) are satisfied, the First Retention Bonus and/or Second Retention Bonus, as applicable, shall not be owed,
earned or paid. Notwithstanding the foregoing, in no event shall the First Retention Bonus or the Second Retention Bonus be deemed a “target bonus” or “Incentive Compensation” under the definition of “Base Amount”
provided for herein. 
  

	 	f.	Section 4.4. The last sentence of Section 4.4 is amended and restated in its entirety as follows. 

“Unless the Executive provides written notification of an event described in the definition of Good Reason within 90 days after the
Executive has actual knowledge of the occurrence of any such event (or in the case of an event described in clause (6) of such definition, within the later of (i) 90 days after the Executive has actual knowledge of the occurrence of any
such event and (ii) September 30, 2014), the Executive shall be deemed to have consented thereto and such event shall no longer constitute Good Reason for purposes of this Agreement.” 

 

	 	g.	Definition of “Good Reason”. The definition of “Good Reason” is amended to delete the word “or” preceding clause (4), and to insert the following text after clause (4).

 “; or (5) the effective date of Executive being replaced by Parent as the Chief Financial Officer of Parent;
provided, however, that in no event shall “Good Reason” be deemed to exist pursuant to clause (5) prior to the date that the Company has completed and filed (i) its financial restatement for the 2011 and 2012 calendar years and
the first quarter of 2013, and (ii) its quarterly reports on Form 10-Q for the fiscal quarters ended June 30, 2013 and September 30, 2013 and annual report on Form 10-K for the fiscal year ended December 31, 2013” 

2. No Retroactive Effect. The amendments to the Agreement provided for herein shall be applicable prospectively from the date of this
Amendment forward, and shall not have applicability with respect to periods under the Agreement prior to the date of this Amendment (except with respect to the changes set forth in Sections 1.1, 2.2 and 2.3, which memorialize arrangements that were
already in effect prior to the date of this Amendment). 
 3. No Other Amendments. Except as otherwise provided herein, the Agreement
shall remain in full force and effect in accordance with its original terms. 
 4. Legal Fees. In connection with the negotiation of
this Amendment, the Company shall pay Executive’s outside counsel fees (subject to the receipt of a customary invoice) in an amount not to exceed $15,000. 

[signature page follows] 

 IN WITNESS WHEREOF, the parties have executed and delivered this Amendment as of the date first
set forth above. 
  

			
	ORTHOFIX INC.
		
	By:	 	/s/ Bradley R. Mason
	Name:	 	Bradley R. Mason
	Title:	 	President and Chief Executive Officer
	
	EXECUTIVE
	
	/s/ Emily Buxton
	Emily Buxton

  

			
	Agreed and Acknowledged:
	
	ORTHOFIX INTERNATIONAL N.V.
		
	 By:
	 	 /s/ Bradley R. Mason

	 Name:
	 	 Bradley R. Mason

	 Title:
	 	 President and Chief Executive OfficerEX-10.1

 Exhibit 10.1 
  

 
 February 21, 2014 

Mr. Jiayue Zhang 
 Chairman and President 

Shanxi Taxus Pharmaceuticals Co., Ltd. 
 Houfangnan, Yutai Rd.
Yuci District 
 Jinzhong City, Shanxi Province 
 China 030600

  

	 	Re:	Strategic Cooperation Between Cardium Therapeutics, Inc. and Shanxi Taxus Pharmaceuticals Co., Ltd.  

Dear Mr. Zhang: 
 This letter is to confirm
the terms of a strategic cooperation between Cardium Therapeutics, Inc., on behalf of itself and its affiliates (individually and collectively “Cardium”) and Shanxi Taxus Pharmaceuticals Co., Ltd. on behalf of itself and its affiliates
(individually and collectively “Taxus”), with such affiliates being those as defined in that certain Stock Purchase Agreement entered into as of February 21, 2014, by and between Cardium and Taxus (the “Stock Purchase
Agreement”). The terms of this strategic cooperation shall be as set forth below, based on the reciprocal obligations of Cardium and Taxus as provided herein and in the Stock Purchase Agreement. 

1. Strategic Cooperation Regarding Cardium Products in China: Taxus agrees that it will, upon request, apply commercially reasonable
efforts to assist Cardium to develop and refine a plan or plans pursuant to which Cardium products and product opportunities may be commercialized in China. Taxus agrees to reasonably assist with Cardium’s execution of such plans at
Cardium’s expense; provided, further, that Taxus shall not be responsible for any out-of-pocket expenses, costs or investments as may be required for the execution of any plan, except as may be subsequently agreed to by the parties in writing.

 2. Strategic Cooperation Regarding Taxus Products in the United States: Cardium agrees that it will, upon request, apply
commercially reasonable efforts to assist Taxus to develop and refine a plan or plans pursuant to which Taxus products and product opportunities may be commercialized in the United States. Cardium agrees to reasonably assist with Taxus’
execution of such plans at Taxus’ expense; provided, further, that Cardium shall not be responsible for any out-of-pocket expenses, costs or investments as may be required for the execution of any plan, except as may be subsequently agreed to
by the parties in writing. 
  

					
		 	 11750 Sorrento Valley Rd., Suite 250, San Diego, CA 92121 • 858.436.1000

 
	 	
		 	  
 www.cardiumthx.com
	 	

 

 
  

 Mr. Jiayue Zhang 

February 21, 2014 
  Page
 2
 
  

 3. Change of Corporate Name: Cardium agrees that following the execution of this
strategic cooperation arrangement and initial closing under the Stock Purchase Agreement, it will promptly take such action and seek appropriate approvals as required under Delaware General Corporation Law to change its name to “Taxus Cardium
Pharmaceuticals Group.” 
 4. Board Appointments: Cardium agrees that following the completion of the initial firm commitment
financing of $2.0 Million under the Stock Purchase Agreement, it will promptly take such action and seek appropriate approvals to increase the size of Cardium’s Board of Directors by two, and to appoint two qualified nominees designated by
Taxus to fill such positions. Cardium further agrees that following the completion of a full $5.0 Million in financing under the Stock Purchase Agreement, it will promptly take such action and seek appropriate approvals to increase the size of
Cardium’s Board of Directors by one additional director, and to appoint a qualified nominee designated by Taxus to fill such position. 

5. Miscellaneous: The miscellaneous provisions of the Stock Purchase Agreement shall apply, to the extent applicable, to this strategic
cooperation arrangement. 
  

	
	Sincerely,
	
	/s/ Christopher J. Reinhard
	Christopher J. Reinhard
	President & Chief Executive Officer

  

			
	Accepted and Agreed to on Behalf of Shanxi Taxus Pharmaceuticals Co., Ltd.
	
	 /s/ Jiayue Zhang

	By:	 	Jiayue Zhang
	Its:	 	Chairman and President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}]]